{"nctId":"NCT01359956","briefTitle":"Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma","startDateStruct":{"date":"2002-04"},"conditions":["Malignant Melanoma","Recurrent Melanoma"],"count":269,"armGroups":[{"label":"A1","type":"EXPERIMENTAL","interventionNames":["Drug: Dacarbazine","Drug: Fotemustine"]},{"label":"A2","type":"EXPERIMENTAL","interventionNames":["Drug: Dacarbazine","Drug: Fotemustine","Drug: Interferon Alfa-2b"]},{"label":"B1","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Dacarbazine"]},{"label":"B2","type":"EXPERIMENTAL","interventionNames":["Drug: Dacarbazine","Drug: Interferon Alfa-2b"]}],"interventions":[{"name":"Dacarbazine","otherNames":[]},{"name":"Fotemustine","otherNames":[]},{"name":"Interferon Alfa-2b","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically confirmed diagnosis of malignant melanoma in advanced stage or recurrent after surgery, and not amenable to further surgery or local therapy.\n* Presence of measurable disease\n* Age \\> or = 18 years and \\< or = 75 years\n* Performance status (ECOG) 0 - 2 (Appendix 2)\n* Life expectancy 続 3 months\n* Adequate bone marrow function (ANC 続 2,000/mmc; PTL 続 100,000/mmc; Hb 続 10 gr/dl), normal liver and renal function (bilirubin \\< 1.25 x N, creatinine \\< 1.25 x N, SGOT, SGPT \\< 3 times upper normal limit of testing laboratory.\n* Written, informed consent prior to study specific procedures, with the understanding that the patient has the right to withdraw from the study at any time, without prejudice.\n* Prior surgery \\> 3 weeks from initiating .\n* If palliative radiation is needed, in case of non target lesions, it must be given prior to initiating chemotherapy. If palliative radiation is required during the study the patient should be permanently discontinued from further treatment.\n* Adequate contraceptive measures during study participation for sexually active patients of child bearing potential must implement.\n\nExclusion Criteria:\n\n* Previous or concurrent malignancies at other sites with the exception of surgically cured carcinoma in-site of the cervix and basal or squamous cell carcinoma of the skin.\n* Prior chemo-immunotherapy ( previous adjuvant immunotherapy is allowed)\n* Known HIV disease.\n* Concurrent treatment with other experimental drugs.\n* Concurrent chemotherapy, immunotherapy, hormonal therapy (excluding contraceptives and replacement steroids), radiation therapy\n* Pregnant or lactating females Previous or concurrent malignancies at other sites with the exception of surgically cured carcinoma in-site of the cervix and basal or squamous cell carcinoma of the skin.\n\nPrior chemo-immunotherapy ( previous adjuvant immunotherapy is allowed) Known HIV disease. Concurrent treatment with other experimental drugs. Concurrent chemotherapy, immunotherapy, hormonal therapy (excluding contraceptives and replacement steroids), radiation therapy","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival (OS)","description":"Overall Survival was defined as the time from the date of randomisation to the date of death from any cause or the date of last follow-up for living patients.\n\nOS curves were estimated with the Kaplan - Meier (K-M) method and treatments were compared with a two - sided log - rank test.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","spread":null},{"groupId":"OG001","value":"8.6","spread":null},{"groupId":"OG002","value":"9.1","spread":null},{"groupId":"OG003","value":"7.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS)","description":"Progression Free Survival (PFS) was defined as the time from the date of randomisation to the date of progression of disease or death from any cause, whichever occurred first, or date of last follow-up for patients without progression and alive at the end of the study.\n\nPFS curves were estimated with the Kaplan - Meier (K-M) method and treatments were compared with a two-sided log-rank test.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":null},{"groupId":"OG001","value":"2.5","spread":null},{"groupId":"OG002","value":"2.8","spread":null},{"groupId":"OG003","value":"2.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response Rate (ORR)","description":"Overall Response Rate (ORR) included Complete Response (CR) and Partial Response (PR).\n\nComplete Response (CR) was defined as disappearance of all symptoms and signs of all measurable disease, lasting for at least four weeks, without appearance of new lesions.\n\nPartial Response (PR) was defined as a \\> 50% reduction in the sum of the products of the perpendicular diameters of all measurable lesions, lasting for at least four weeks, without appearance of new lesions or enlargement of existing lesions.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"33","spread":null},{"groupId":"OG002","value":"34","spread":null},{"groupId":"OG003","value":"31","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Related Toxicity","description":"worst grade CTC toxicity, for each cycle and overall, will be reported for each treatment arm","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"129","spread":null},{"groupId":"OG001","value":"122","spread":null},{"groupId":"OG002","value":"119","spread":null},{"groupId":"OG003","value":"132","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":62},"commonTop":["Nausea/Vomiting","Diarrhoea"]}}}